AtheroGenics, Inc. · Alpharetta, GA United States ·(OTC: AGIXQ)

Drug company AtheroGenics develops drug candidates for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease. Its lead candidate, AGI-1067, is an oral drug intended to improve blood sugar levels. Development of the therapeutic compound is ongoing despite disappointing results from a major AGI-1067 clinical trial, which led to the termination of a licensing agreement with AstraZeneca and an organizational restructuring that cut AtheroGenics' workforce in half in 2007. The company's alliance with Astellas Pharma on a second anti-inflammatory candidate, organ transplant drug AGI-1096, also ended. In 2008 the company filed for Chapter 11 bankruptcy protection. To read the full description, subscribe now.